Northwest Biotherapeutics to start DCVax-LB trial in lung cancer

By Lisa Kerner

Charlotte, N.C., Sept. 7 - Northwest Biotherapeutics, Inc. said it was granted clearance from the Food and Drug Administration to begin phase 1 clinical testing of its personalized therapeutic cancer vaccine, DCVax-LB, in non-small cell lung cancer.

Endpoints of the trial will be progression-free survival and overall survival, according to the Bothell, Wash.-based biotechnology company.

DCVax-LB is an extension of DCVax personalized cancer vaccine that has shown significant delay in disease progression in clinical trials in primary brain and prostate cancers.

"The same DCVax platform can be used for the treatment of many different tumor types, since it incorporates all of the biomarkers from the patient's tumor," president Alton Boynton said in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.